Pathogenesis of Psoriasis: The Role of Pro-Inflammatory Cytokines Produced by Keratinocytes by Anna Balato et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Pathogenesis of Psoriasis: The Role of 
 Pro-Inflammatory Cytokines Produced  
by Keratinocytes  
Anna Balato, Nicola Balato, Matteo Megna,  
Maria Schiattarella, Serena Lembo and Fabio Ayala 
Department of Dermatology – University of Naples Federico II  
Italy  
1. Introduction  
Psoriasis is a chronic, inflammatory skin disease affecting 2 to 3% of the white population 
(Gudjonsson & Elder, 2007). It is a multifactorial disease since its development depends on a 
complex interplay of genetic and environmental factors. As no pathogen has been 
consistently identified within psoriatic plaques (indeed skin infections are rare in lesions 
because of antimicrobial peptides) (Nomura et al., 2003), an autoimmune basis for the 
chronic inflammation is the dogma for this complex disorder. Psoriasis is characterized by 
macroscopic (clinical) and corresponding microscopic (histological) skin alterations and 
leads to considerable impairment of the quality of life of the affected patients. Special forms 
of psoriasis (e.g. arthropathic form) can be accompanied by severe extra-cutaneous changes.  
2. Psoriasis pathogenesis 
Psoriasis is usually identified by erythematous, raised, scaly skin lesions. These clinical 
features are explained by impressive growth and dilation of superficial blood vessels 
(elongated/hyperplastic capillaries in the papillary dermal region) and equally impressive 
hyperplasia of the epidermis. Epidermal growth occurs in a pattern termed ‘‘psoriasiform’’ 
hyperplasia, which describes both elongated rete pegs, thickening (acanthosis), and 
differentiation changes (Krueger & Bowcock, 2005). In psoriatic epidermis, keratinocytes 
proliferate and mature rapidly so that terminal differentiation, normally occurring in 
granular keratinocytes and then squamous corneocytes, is incomplete. Hence, squamous 
keratinocytes aberrantly retain intact nuclei (parakeratosis) and release few extracellular 
lipids that normally cement adhesions of corneocytes. The failure of psoriatic corneocytes to 
stack normally and to secrete extracellular lipids cause scaling and a break in the protective 
barrier whereas marked dilation of blood vessels in the dermis causes the visible redness of 
psoriatic skin lesions. The extensive infiltration of mononuclear immune cells in the dermis 
and epidermis (T cells and dendritic cells in the dermis and polymorphonuclear leucocytes 
such as neutrophils within small foci in the stratum corneum) is another defining feature of 
psoriasis histopathology and a key point of its pathogenesis. The pathogenesis of psoriasis is 
considered to be an immunologically mediated process that takes place upon a favourable 
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genetic background. According to this view, the presence of a yet unknown (auto)-antigen 
causes the generation of effector T-cells that infiltrate the skin and initiate the inflammatory 
process (Wolk et al., 2009a). Over its course, cutaneous infiltration of various immune cell 
populations and, subsequently, an activation of numerous immune and tissue cells in the 
skin take place. Secreted cytokines from activated cells then induce keratinocyte alterations 
such as excessive growth and aberrant differentiation forming the basis of the epidermal 
acanthosis, hyperkeratosis and parakeratosis which characterize psoriasis plaques. The 
trigger of keratinocyte response is thought to be the activation of the cellular immune 
system, with T cells, dendritic cells  and various immune-related cytokines and chemokines 
implicated in pathogenesis. Rather than viewing psoriasis as a disease caused by a single 
cell type or a single inflammatory cytokine, it is probably best to conceptualize the disease 
pathogenesis as linked to many interactive responses among infiltrating leucocytes, resident 
skin cells, and an array of pro-inflammatory cytokines, chemokines, and chemical mediators 
produced in the skin (Lowes et al., 2007). Fundamentally two different cell types interact in 
the formation of a psoriatic lesion: keratinocytes and mononuclear leukocytes. Whereas 
keratinocytes might be viewed only as bystander cells in terms of immune activation, it is 
more likely that they are active participants in the recruitment and activation of leukocytes  
in psoriatic lesions. Thus, there are two sets of interactive cellular responses in the psoriatic 
lesion that potentially create a ying/yang relationship; the balance between the activation of 
innate and acquired immune cell types, and the factors produced by epidermal 
keratinocytes that directly affect T cells and dendritic cells, and vice versa. Psoriasis is 
considered a T helper 1 (Th1) condition, characterized by the production of interferon-
gamma (IFN-Ǆ) and tumor necrosis factor alpha (TNF-ǂ) under the influence of interleukin-
12 (IL-12). However, there is increasing evidence of the importance of a novel T cell 
population, Th17 cells, in this inflammatory disease. Th17 cells are stimulated by IL-23 
(which shares the p40 subunit with IL-12) to produce IL-17 and also IL-22, which has 
recently been shown to be a major driver of acanthosis in psoriasis, and so is a novel target 
for treatment. Effector cells of innate immunity including neutrophils, plasmacytoid 
dendritic cells (plasmocytoid DCs) and CD11c+ dendritic cells (myeloid DCs) are involved 
and present in psoriatic lesions creating a very intricate and complex network of interactions 
which is the base of the pathogenetic process of psoriasis (Nograles et al., 2010). An 
interplay between environmental and genetic factors sets the scene for disease-initiating 
events. Initial triggers such as physical trauma or bacterial products start a cascade of events 
that include the formation of DNA-LL-37 complexes, activation of plasmocytoid dendritic 
cells and secretion of interferon-ǂ (IFN-ǂ). IFN-ǂ secreted by plasmocytoid dendritic cells 
promotes the activation of myeloid dendritic cells (Nestle et al., 2005). Activated myeloid 
dendritic cells migrate into draining lymph nodes and induce the differentiation of naive T 
cells into effector cells such as Th17 or type 17 cytotoxic T cells (Tc17) and Th1 or type 1 
cytotoxic T cells (Tc1) (Nestle et al., 2010). Effector cells recirculate and slow down in skin 
capillaries in the presence of selectin-guided and integrin-guided receptor-ligand 
interactions. Immune cells expressing the chemokine receptors CCR6, CCR4, and CXCR3 
emigrate into skin tissue along chemokine gradients. Dendritic cells and T cells form 
perivascular clusters and lymphoid-like structures around blood vessels in the presence of 
chemokines such as CCL19 produced by macrophages. A key checkpoint is the migration of 
T cells from the dermis into the epidermis; this migration is controlled through the 
interaction of ǂ1ǃ1 integrin (very late antigen 1 [VLA-1]) on T cells and collagen IV at the 
basement membrane (Conrad et al., 2007). Unconventional T cells, including natural killer T 
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cells (NKT), contribute to the disease process. Key processes during disease maintenance are 
the presentation of putative (auto)-antigens to T cells, the release of IL-23 by dermal 
dendritic cells, the production of pro-inflammatory mediators such as IL-17A, IL-17F, IL-22 
by Th17 and Tc17 cells and IFN-y and TNF-ǂ by Th1 and Tc1 cells. These mediators act on 
keratinocytes leading to the activation, proliferation and production of antimicrobial 
peptides (AMPs) (e.g., LL-37 cathelicidin and ǃ-defensins) and chemokines (e.g., CXCL1, 
CXCL9 through CXCL11 and CCL20), and S100 proteins (e.g., S100A7-9) (Nestle et al., 2010). 
These soluble mediators feed back into the pro-inflammatory disease cycle and shape the 
inflammatory infiltrate (Fig.1). In fact keratinocyte products influence immune activation, 
and products of activated lymphocytes alter keratinocyte responses, including the induction 
of new adhesion molecules for T cells. However although intrinsic alterations in 
keratinocytes are crucial for the development of psoriatic lesions, a deregulated function of 
other resident skin cells, such as fibroblasts and endothelial cells, may also contribute to the 
pathogenesis of psoriasis. Epidermal-dermal cell interaction is a determinant for the 
maintenance of the psoriatic phenotype because it guarantees the local production of growth 
factors and cytokines stimulating keratinocyte proliferation. An important paracrine loop  
 
Fig. 1. Main actors of psoriasis pathogenesis. 
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operating between keratinocytes and fibroblasts that culminates with keratinocyte 
proliferation is triggered by IL-1: IL-1ǂ and IL-1ǃ neutralization and IL-1 receptor antagonist 
significantly reduced keratinocyte growth through the abrogation of keratinocyte growth 
factor (KGF) production by fibroblasts. However, IL-1 is unlikely to be the only regulator of 
KGF production by fibroblasts, and indeed other keratinocyte-derived factors, such as 
parathyroid hormone–related protein (PTHrP), induce KGF expression. In addition 
fibroblast growth factor (FGF) family members and granulocyte-macrophage colony 
stimulating factor (GM-CSF) also play a particularly important role in the fibroblast-driven 
regulation of keratinocyte proliferation (Albanesi et al., 2007). Moreover, the activated 
phenotype of lesional endothelial cells are believed to play a central role in the pathogenesis 
of psoriasis and are determined by the expression of a variety of membrane and soluble 
factors mainly responsible for T-cell recruitment in the skin like adhesion molecule 1 
(ICAM-1). A key point is the endothelium expression of certain chemokines involved in the 
arrest of circulating T lymphocytes at inflammatory sites: upon exposure to inflammatory 
signals, mainly represented by TNF-ǂ and IL-1, endothelial cells express a broad array of 
chemokines, including CCL20/MIP-3ǂ, CXCL12/SDF-1, CCL21/SLC, CCL17/TARC, 
CCL2/MCP-1, CXCL10/IL-8, CCL5/RANTES, CXCL1/Gro-ǂ, and CCL4/MIP-1ǃ 
(Girolomoni et al., 2004).   
In summary, feedback loops involving keratinocytes, fibroblast and endothelial cells 
contribute to tissue reorganization with endothelial cell activation and proliferation and 
deposition of extracellular matrix. The hypothesis of cytokine/chemokine network in 
psoriasis proposed a central role of pro-inflammatory cytokines, including TNF-ǂ. 
3. A special look at the pathogenetic functions of keratinocytes  
Besides erythema, impressive hyperkeratosis manifesting as large, silvery scales, is clinically 
the most visible pathology and represents a hallmark of psoriasis. This typical and 
characteristic epidermal involvement has in the past led to discussions on whether 
hyperproliferation and altered differentiation of epidermal keratinocytes occur indeed only 
in response to skin inflammation or whether keratinocytes themselves have their share in 
initiation and/or propagation of psoriasis. Whereas it is widely accepted today that 
keratinocytes have the potential to actively participate and modulate immune reactions in 
the skin their role as initiators or amplifiers of the inflammatory reaction in psoriasis is still 
not so clear (Tschachler, 2007). Some evidence indicates that the exposure of altered auto-
antigens by keratinocytes could be directly responsible for the activation and expansion of 
certain T-cell subpopulations in psoriatic skin (Bos et al., 2005). A keratinocyte-derived 
candidate auto-antigen is keratin 17. Patients with active psoriasis have an increased 
frequency of circulating Th1 cells reacting to peptides from keratin 17 that shares ALEEAN 
aminoacidic sequence with the streptococcus M-protein. Using a new approach termed 
SErological identification of Recombinant EXpressed antigens (SEREX), new auto-antigens 
were found in the serum of patients with psoriasis (Jones et al., 2004). Keratin 13, 
heterogeneous ribonucleprotein-A1, and a previously uncharacterized protein, FLJ00294, 
were identified by SEREX as representative antigens in psoriatic patients, although auto-
reactivity for these proteins was also detected in control subjects without psoriasis. 
Keratinocytes could be indirectly responsible for the activation of pathogenetic T cells 
through the exposure to viral or bacterial products. Under the influence of IL-17 and IL-22, 
keratinocytes, are able to produce AMPs like human beta defensin 2, and S100 proteins 
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(Nograles et al., 2008). The expression of another antimicrobial peptide, LL-37 cathelicidin, 
can also be enhanced by IL-17 in the presence of vitamin D3 (Peric et al., 2008). These 
proteins may function as key inflammation inducers in psoriasis, and at the same time 
decrease skin infections under conditions of a dysfunctional epidermal barrier. Infections or 
injury to the skin can promote lesion formation in susceptible individuals and these triggers 
have been shown to stimulate keratinocyte production of the antimicrobial LL-37 
cathelicidin that, when complexed with self-DNA, binds to TLR9 on plasmocytoid DCs. 
These cells produce massive amounts of IFN-ǂ and are implicated in the initiation of psoriasis 
lesions (Lande et al., 2007). Accordingly, patients treated with a topical plasmocytoid DCs 
agonist, imiquimod, up-regulate IFN-ǂ and experience exacerbations in psoriasis. In addition 
to stimulating plasmocytoid DCs, LL-37 has been shown to complex with self-RNA to trigger 
the activation of myeloid dendritic cells (myeloid DCs) through TLR8. This leads to production 
of TNF-ǂ and IL-6, and promotes their differentiation into mature dendritic cells (Ganguly et 
al., 2009). Because myeloid DCs in psoriasis have been shown to produce IL-23 it is plausible 
that self-RNA complexes might potentially initiate the inflammatory cascade leading to 
expansion and activation of Th17 cells (Nograles et al., 2010).  
Recent investigations identified high levels of osteopontin (OPN) in psoriatic plaques 
(Buommino et al., 2009). Osteopontin is produced by both keratinocytes and activated T 
cells. It is a phosphorylated acidic glycoprotein of pleiotropic properties and has been 
recently recognized as a potential inflammatory cytokine. A model for the role of OPN in 
Th1 ⁄ Th17 psoriatic disease was so suggested. After activation of myeloid DCs that express 
OPN, they migrate to skin draining lymph nodes and polarize naive T cells towards a Th1 
and Th17 phenotype. In addition OPN secreted by keratinocytes attracts additional 
inflammatory cells. Moreover OPN inhibits keratinocyte apoptosis thereby supporting 
enhanced epidermal proliferation, and, through a pro-angiogenic effect on microvascular 
endothelial cells, OPN also promotes vessel formation subsequently supporting the influx of 
inflammatory cells (Buback et al., 2009).  
3.1 Keratinocytes and cytokines 
Cutaneous and systemic over-expression of various pro-inflammatory cytokines has been 
demonstrated in psoriasis. Psoriatic keratinocytes are able to produce and release IL-1ǂ, IL-
1ǃ, IL-6, IL-15, IL-18 and IL-20, all of them involved in the development of different 
alterations which compose the complex and intricate net of psoriasis pathogenesis (Tab. 
1).The cellular composition of the inflammatory infiltrate within the psoriatic plaques as 
well as hyperproliferation of keratinocytes and so the whole pathogenetic process of 
psoriasis appears to be mediated by these cytokines (Wojas-Pelc et al., 2006).  
3.1.1 Keratinocytes and IL-1α & IL-1β 
IL-1 is a pro-inflammatory cytokine stimulating, among others, IL-2 and IFN-Ǆ production 
through activated T cells. IL-1 activates neutrophils, monocytes, eosinophils and 
basophils, triggers production of TNF-ǂ, IL-6, IL-8 by macrophages, and in autocrine 
fashion, IL-1 synthesis. IL-1 promotes proliferation of bone marrow cells, B lymphocytes, 
neutrophils, macrophages and platelets (Dinariello, 2002). In psoriasis, keratinocytes are 
the main source of IL-1ǂ and IL-1ǃ in the skin stored in the form of precursor particles 
(Zepter et al., 1997). Monocytes/macrophages, activated endothelial cells, fibroblasts and 
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Langerhans cells (LCs) are additional IL-1 sources (Yoshinaga et al., 1995). Normal 
keratinocytes do not contain a biologically active form of interleukin 1ǃ-converting 
enzyme (ICE), and almost all IL-1 activity in the healthy epidermis results from the 
activity of IL-1ǂ. In transgenic mouse models, IL-1ǂ production in the basal layer of the 
epidermis leads to development of inflammatory lesions characterized by erythema and 
histology resembling psoriasis  (Groves et al., 1995). Although IL-1 expression in the 
psoriatic epidermis appears altered, data on this finding are often conflicting. Some 
studies showed that IL-1ǂ levels in psoriatic lesions were decreased or below detection 
limits in comparison to non-lesional and healthy skin (Okubo & Koga, 1998), whereas 
others demonstrated increased levels of IL-1ǃ (Debets et al., 1997). Serum levels of IL-1ǂ 
and IL-1ǃ were low both in patients and in healthy controls. Increased levels of IL-1ǂ and 
IL-1ǃ were noted in supernatants of monocyte cultures obtained from patients with 
psoriasis (Okubo & Koga, 1998). Peripheral blood mononuclear cells (PBMCs) of inactive 
psoriasis patients produced lower levels of IL-1ǂ and IL-1ǃ than the cells obtained from 
patients with active psoriasis, although still higher than those of healthy controls. The 
production of IL-1ǃ by PBMCs from psoriatic patients positively correlated with disease 
severity (Mizutani et al., 1997). Higher levels of IL-1ǃ in blister fluid than in serum 
support the hypothesis that this cytokine is locally produced in psoriatic lesions. Despite 
fairly strong arguments for the key role of IL-1 in the activation of psoriasis, there is 
scarcity of data on the use of IL-1 antagonists in psoriasis treatment.  
 
Cytokines Role in psoriasis 
IL-1 Stimulation of IL-2 and IFN-Ǆ production 
through activated T cells and of TNF-ǂ, IL-
6, IL-8 by macrophages, and in autocrine 
fashion, of IL-1 synthesis. 
IL-6 Regulation of growth and differentiation of 
epidermal cells and stimulation of Th17 
cells  differentiation. 
IL-15 Anti-apoptotic effects on lymphocytes and 
keratinocytes; stimulation of IL-17 
expression, promotion of T cell and 
monocyte activation, production of 
cytokines implicated in the pathogenesis of 
psoriasis, including IFN-Ǆ and TNF-ǂ. 
IL-18 Induction of several chemokines in 
fibroblasts and neutrophils, increased T-
cell adhesion to extracellular matrix 
ligands, induction of angiogenesis, 
induction of chemotaxis in plasmacytoid 
dendritic cells. 
IL-20 Inhibition of normal terminal 
differentiation of keratinocytes, induction 
of anti-bacterial proteins. 
Table 1. Roles of cytokines released by psoriatic keratinocytes. 
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3.1.2 Keratinocytes and IL-6 
IL-6 is involved in the growth and differentiation of dermal and epidermal cells (Hirano, 
1998), growth and differentiation of cytotoxic cells, activation of natural killer cells (NK) and 
maturation of hematopoietic stem cells (Pietrzak et al., 1999). Furthermore it acts as a 
chemotactic factor for T cells, and thus can directly stimulate T-cell migration to the 
epidermis. Increased levels of mRNA of IL-6 and its receptor were observed in psoriatic  
lesions, suction blister fluid and in keratinocytes (Krasowska et al., 1998). Previous studies 
have also shown a high level of IL-6 in plasma/serum of patients with psoriasis (Galadari & 
Sheriff, 2005; Grossman et al., 1989). Higher IL-6 levels were observed in psoriatic lesions 
compared to non-lesional and normal healthy skin (Chang et al., 1992; Grossman et al., 
1989). Classical anti-psoriatic therapies such as phototherapy (PUVA, UVB), systemic 
corticosteroids and methothrexate lead to normalization of IL-6 levels (Mizutani et al., 1997). 
Both non-lesional and lesional psoriatic keratinocytes produce IL-6 (Grossman et al., 1989; 
Krasowska et al., 1998; Zalewska et al., 2006). IL-1 and TNF-ǂ activate keratinocytes to 
produce IL-6. Koebner phenomenon is likely to result from the increased activity of IL-6 and 
its receptor in psoriasis (Grossman et al., 1989). Many studies show that IL-17F is able to 
induce IL-6 production both in normal human epidermal keratinocytes and in mouse skin 
(Fujishima et al., 2010). Moreover CD4+ T cells in skin from psoriasis patients express IL-17F 
and recent studies have demonstrated increased expression of IL-6 in IL-17F-overexpressing 
mice, thus further supporting a role of IL-17F in the induction of IL-6 (Hurst et al., 2002; 
Yang et al., 2008). IL-6 could directly contribute to the epidermal hyperplasia seen in 
psoriatic epithelium as well as affecting the function of dermal inflammatory cells. 
Moreover, it has been demonstrated that IL-6 induces Th17 cell differentiation in humans 
(Ishigame et al., 2009). Taken together, all these data suggest that IL-17F-induced IL-6 
produced by keratinocytes promotes the development of Th17 cells as an autocrine 
regulator. Thus, the IL-17F/IL-6 axis may enhance inflammation of the lesional skin in 
psoriasis (Fujishima et al., 2010).  
3.1.3 Keratinocytes and IL-15 
IL-15 is a pro-inflammatory cytokine involved in chronic inflammatory processes. It is a key 
factor controlling the activation, proliferation and survival of NK cells (Fehniger & Caligiuri, 
2001; Liu et al., 2000). IL-15 is also a strong chemotactic factor for leukocytes. This cytokine 
triggers angiogenesis and exerts strong anti-apoptotic effects, especially on lymphocytes, 
hepatocytes and keratinocytes (Berard et al., 2003; Rückert et al., 2000). Furthermore, it 
stimulates the expression of IL-17 by T cells (Elder, 2007). Elevated levels of IL-15 were 
noted in the lesional psoriatic skin (Elder, 2007; Rückert et al., 2000; Yano et al., 2003). 
Monocytes and macrophages represent the main source of IL-15 (Fehniger & Caligiuri, 2001; 
Musso et al., 1999) in lesional psoriatic skin, as well as keratinocytes (McInnes & Gracie, 2004; 
Yano et al., 2003). Lesional keratinocytes are strong producers of IL-15, which not only appears 
critical in the promotion of T cell and monocyte activation and, hence, in the maintenance of 
the local pro-inflammatory milieu, but also in the keratinocyte self-protection from apoptosis 
(Rückert et al., 2000); the pathogenic effect of this cytokine in psoriasis probably results from 
the stimulation of proliferation and activation of T cells and pro-inflammatory cytokines 
release (including TNF-ǂ). Recent genetic studies (Elder, 2007) further supported the role of IL-
15 as an important factor in psoriasis pathogenesis: IL-15 acts as a growth factor for CD8+ T 
cells, which infiltrate the epidermis during the development of psoriatic lesions, triggers 
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inflammatory cell recruitment, angiogenesis, and production of other cytokines implicated in 
the pathogenesis of psoriasis, including IFN-Ǆ and TNF-ǂ.  
3.1.4 Keratinocytes and IL-18 
IL-18 exerts its activity on the human defense system in inflammatory, infectious and 
autoimmune diseases (Dinarello, 2006). IL-18 over-production stimulates the recruitment of 
dendritic cells to the site of inflammation (Gutzmer et al., 2003). IL-18, especially together 
with IL-12, triggers the production of IFN-Ǆ in many immunocompetent cells, including NK 
cells, T helper and cytotoxic cells. Subsequently, IFN-Ǆ decreases Th2 response and enhances 
Th1 response by stimulating cytotoxic T cells (Ericson et al., 2004). Thus, IL-18 possesses the 
capacity to stimulate innate immunity as well as Th1-mediated responses (Nakanishi et al., 
2001). IL-18 overproduction is characteristic for many diseases including psoriasis 
(Nakanishi et al., 2001). The role of IL-18 in psoriasis has not been fully elucidated. It is 
speculated that IL-18 produced by human keratinocytes enhances IFN-Ǆ production in 
inflammation and thus IL-18 seems to be a promising target in Th1-type inflammatory 
diseases, like psoriasis (McKenzie et al., 2002; Ohta et al., 2001). Its expression in psoriasis is 
significantly enhanced in supra-basal keratinocytes (Flisiak et al., 2006; McKenzie et al., 
2002; Ohta et al., 2001). Reverse transcription polymerase chain reaction (RT-PCR) revealed IL-
18 mRNA levels to be two to eight times higher in psoriatic skin biopsies than in the non-
lesional psoriatic skin and healthy controls. Overexpression of IL-18 was observed in 
keratinocytes of the whole epidermis in psoriatic lesions and in the basal layer of non-lesional 
epidermis compared to only slight IL-18 expression in the epidermis of healthy controls 
(McKenzie et al., 2002). McKenzie et al. reported six to eight-fold higher levels of the IL-18 
receptor mRNA in the epidermis of psoriatic lesions compared to non-lesional and healthy 
control skin. Moreover total IL-18 protein levels were found to be 3.5 times higher in the active 
and progressive psoriatic epidermis compared to the normal and stable, plaque-type psoriatic 
epidermis. To date, there are only a few studies on IL-18 in the blood of psoriatic patients 
(Flisiak et al., 2006, Gangemi et al., 2003), which revealed increased plasma IL-18 levels in 
psoriatic patients in comparison to controls. IL-18 might act in the early phases of psoriasis via 
IFN-Ǆ independent routes, such as: a) induction of several chemokines in fibroblasts and 
neutrophils (Leung et al., 2001; Morel et al., 2001); b) increased T-cell adhesion to extracellular 
matrix ligands (Ariel et al., 2002); c) induction of angiogenesis (Park et al., 2001); d) induction 
of chemotaxis in plasmacytoid dendritic cells (Kaser et al., 2004). Thus, IL-18 could be involved 
in the regulation of early inflammatory events by promoting the recruitment and adhesion of 
the immune system cells to the inflamed sites. However, whether IFN-Ǆ-dependent or 
independent mechanisms are responsible for the IL-18 activity in early stages of psoriatic 
plaque development remains to be elucidated.  
3.1.5 Keratinocytes and IL-20 
IL-20 was demonstrated to promote hyperproliferation of keratinocytes by activating IL-20 
receptor to modulate skin inflammation. It was also reported that IL-20 induced IL-6 and TNF-
ǂ in monocytes, stimulated the expression of keratinocytes growth factor (KGF), IL-6, TNF-ǂ 
and reactive oxygen species (ROS) in CD8+ T cells (Wei et al., 2006). In psoriasis, the two most 
important effects of IL-20 are the inhibition of normal terminal differentiation of keratinocytes 
and the induction of anti-bacterial proteins (Wolk et al., 2009a). Keratinocyte terminal 
differentiation is the apoptosis-like process that generates corneocytes for the desquaming 
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stratum corneum from living keratinocytes of the upper (granular) epidermis layer (Candi et 
al., 2005). In psoriatic lesions, which contain high levels of IL-20, this process is altered. 
Furthermore, IL-20 simultaneously enhance the K16 expression, a keratin known to be up-
regulated in psoriatic lesions and associated with keratinocyte regeneration (Wolk et al., 2006, 
2009b). Apart from the inhibition of normal terminal differentiation of keratinocytes, IL-20 in 
addition to other mediators (Kanda & Watanabe, 2008), induce a state of enhanced 
antimicrobial defence of the epidermis by inducing a range of antimicrobial proteins (Sa et al., 
2007; Wolk et al., 2004, 2006). In psoriatic lesions IL-20 expression was found preferentially in 
basal and supra-basal keratinocytes above the dermal papillae (Romer et al., 2003; Wolk et al., 
2009a). Most interestingly, IL-17 and TNF- amplified the IL-22 induced production of IL-20 in 
keratinocytes. In summary, the T/NK cell cytokine IL-22 induces the keratinocyte secretion of 
IL-20 as a second mediator that has very similar effects to its own. IL-20, therefore, may, to 
some extent, further amplify and/or prolong the IL-22 action on the keratinocyte 
differentiation that leads to the characteristic epidermal changes observed in psoriasis.  
3.1.6 Keratinocytes and other cytokines 
TNF-ǂ is a key pro-inflammatory cytokine with an important pathogenetic role in psoriasis 
and psoriatic arthritis. The evidence includes further observations that a variety of anti-
TNF-ǂ approaches such as monoclonal antibodies and fusion proteins of soluble TNF-ǂ 
receptors are effective therapies both in psoriasis and psoriatic arthritis. As for TNF-ǂ itself, 
production of this cytokine is mainly attributed to immune cells (Lowes et al., 2007); 
however, it is noteworthy that keratinocytes are also able to elaborate TNF-ǂ (Gottlieb at al., 
2005). In psoriasis, the inflammatory response to TNF-ǂ could be self-sustaining: activated 
dendritic cells are the major source of TNF-ǂ in psoriasis lesions (Boyman et al., 2004) and at 
the same time TNF-ǂ mRNA is induced in keratinocytes after TNF-ǂ exposure (Gottlieb et 
al., 2005). Low level of TNF-ǂ is present in the upper layer of the healthy epidermis, but its 
synthesis and release from keratinocytes are greatly augmented by injury, infection and UV 
irradiation. Of the two distinct cell-surface receptors for TNF-ǂ, TNFR1 and TNFR2, 
keratinocytes mainly express TNFR1 (Kondo & Sauder, 1997). The binding of TNF-ǂ to 
TNFR1 triggers a series of intracellular events resulting in the activation of transcription 
factors, including NF-KB, AP-1, CCAAT enhancer-binding protein-ǃ, and others, which are 
responsible for the induction of genes important for diverse biological processes, including 
cell growth and death and immune, inflammatory, and stress responses (Banno et al., 2004). 
TNF-ǂ activates the immune responses through inducing the production of additional 
signals, such as IL-1 and IL-8, transforming growth factor type-ǃ (TGF-ǃ) and ICAM-1. 
Psoriatic keratinocytes are also an important source of IL-7. Increased IL-7 levels were 
observed in both the psoriatic skin and serum of psoriatic patients (Bonifati et al., 1997; 
Pietrzak et al., 2008). However, no correlation between IL-7 levels and psoriasis area severity 
index (PASI) score was observed. In addition, IL-7 levels did not decrease after effective 
anti-psoriatic treatment, which suggests that this cytokine could not be regarded as a marker 
of the disease activity. IL-7 is a pleiotropic cytokine playing an essential role in the 
development and differentiation of T cells. IL-7 regulates survival, proliferation and 
cytotoxicity of maturation of T cells at the periphery. Furthermore, IL-7 together with IL-2 
and IL-12, can induce the synthesis of IFN-Ǆ, while, in turn, IFN-Ǆ induces IL-7 secretion by 
keratinocytes (Ariizumi et al., 1995). In psoriasis IL-7 seems to play a key role in driving 
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reciprocal interactions between epithelial cells (keratinocytes) and T-lymphocytes. The 
concomitant T-lymphocyte activation may be dependent on IL-7, and therefore the 
subsequent events driving toward the clinical expression and persistence of psoriasis may 
be IL-7 mediated (Bonifati et al., 1997). All these findings suggest an involvement of IL-7 in 
psoriasis, although further studies are warranted to elucidate the exact role of this molecule 
in the cytokine network of psoriasis pathogenesis. 
3.2 Keratinocytes and chemokines 
Keratinocytes produce many different types of chemokines involved in the recruitment of 
immune cells in the skin. For this reason epidermal cells can play a fundamental role in 
collecting all the immune cells which are implicated in the beginning of the cutaneous 
inflammation process that characterize psoriatic disease. Specifically, keratinocytes release 
IL-8 (CXCL8) and related chemokines which are responsible for the intra-epidermal 
collection of neutrophils and so to the formation of subcorneal microabscesses, a 
characteristic feature of psoriasis (Nickoloff & Turka, 1994); CCL2 (MCP-1), CCL5 
(RANTES), CXCL10 (IP-10), and other CXCR3 ligands are responsible to attract 
predominantly monocytes and Th1 cells, (Gillitzer et al., 1993; Gottlieb et al., 1998), whereas 
CCL20 (MIP-3ǂ) recruits immature Langerhans cells, dendritic cells, and CLA+ T cells 
(Dieu-Nosjan et al., 2000; Homey et al., 2000) (Tab. 2).  
 
Chemokines Roles
IL-8 (CXCL8) Intra-epidermal recruitment of neutrophils  
CCL-2 (MCP-1)
CCL5 (RANTES) 
CXCL10 (IP-10)
Recruitment of monocytes and Th1 cells 
CCL20 (MIP-3ǂ) Recruitment of dendritic cells, CLA+ T 
cells and immature Langherans cells 
Table 2. Roles of chemokines produced by psoriatic keratinocytes. 
3.3 Keratinocytes and other products 
Psoriatic keratinocytes are a reservoir of inflammatory mediators. Under the influence of 
pro-inflammatory cytokines such as IFN-Ǆ, TNF-ǂ, IL-23, and IL-17, keratinocytes express a 
plethora of mediators, not only cytokines, thereby contributing to amplifying the 
inflammatory response implicated in the pathogenesis of psoriasis (Albanesi et al., 2005). 
Apart from pro-inflammatory cytokines as IL-1ǂ, IL-1ǃ, IL-6, IL-15, IL-18 and IL-20 psoriatic 
keratinocytes are able to produce other important factors involved in the development of the 
psoriatic process like vascular endothelial growth factor (VEGF) and CD1d (Tab. 3). 
 
Factors Functions
VEGF Stimulation of angiogenesis, enhancement 
of vascular permeability, induction of 
keratinocytes hyperproliferation in an 
autocrine manner.
CD1d Activation of CD161+ NK T cells and their 
stimulation to secrete IFN-Ǆ.
Table 3. Roles of VEGF and CD1d in psoriasis. 
www.intechopen.com
 
Pathogenesis of Psoriasis: The Role of Pro-Inflammatory Cytokines Produced by Keratinocytes 
 
19 
3.3.1 Keratinocytes and VEGF 
The typical erythema of psoriatic lesions is due to the increased, dilated, and tortuous 
capillaries that extend between the epidermal columns protruding into the dermis. The 
formation of new blood vessels starts with early psoriatic changes and disappears with 
disease clearance. Several angiogenic mediators like VEGF, hypoxia inducible factors, 
angiopoietins and pro-angiogenic cytokines, such as TNF-ǂ, IL-8 and IL- 17, are involved in 
psoriasis development (Heidenreich et al., 2009). Interestingly, already in uninvolved, non-
lesional skin significant over-expression of several VEGF isoforms was observed in patients 
as compared to healthy skin of normal volunteers (Henno et al., 2009). These findings 
suggest that angiogenesis is also one of the key features in the pathogenesis of psoriasis and 
various recent studies focused on the identification and role of pro-angiogenic mediators in 
psoriatic skin. In general, angiogenesis is tightly regulated by a balance between pro- and 
anti-angiogenic mediators (Heidenreich et al., 2009). VEGF, hypoxia-inducible factor-1ǂ 
(HIF-1ǂ), TNF-ǂ, IL-8 and angiopoietins are considered to be the main players responsible 
for the increased vessel formation in psoriasis (Creamer et al., 2002; Heidenreich et al., 2008). 
Interestingly, several small molecules as well as modern biologics used for systemic therapy 
of psoriasis have been shown to provide not only immune regulatory effects but also 
influence endothelial cell biology (Heidenreich et al., 2008). Thus, direct targeting of 
angiogenesis could help both to dissect psoriasis pathogenesis and to develop new 
therapeutic strategies for psoriasis treatment by blocking angiogenic pathways driving 
cutaneous inflammation. Strongly increased production of VEGF by keratinocytes has been 
found in psoriasis (Detmar et al., 1994). Furthermore, over-expression of VEGF in the 
epidermis of mice triggered sub-epidermal angiogenesis and increased leukocyte adhesion 
to these vessels (Detmar et al., 1998), and later in life, these animals develop hyperkeratotic 
skin lesions with a resemblance to psoriasis (Xia et al., 2003). VEGF signaling often 
represents a critical rate-limiting step in physiological angiogenesis (Ferrara et al., 2003). 
Under physiological conditions, VEGF promotes growth of endothelial cells (ECs) derived 
from arteries, veins and lymphatic vessels. VEGF delivery also induces lympho-
angiogenesis in mice and it is known to be a survival factor for endothelial cells both in vitro 
and in vivo. However, VEGF is also known as a vascular permeability factor, based on its 
ability to induce vascular leakage. In the meantime it is well established that such 
permeability enhancing activity underlies significant roles of this molecule in inflammation 
and other pathological circumstances (Ferrara et al., 2003). Besides its potential role in 
causing aberrant angiogenesis and vascular leakage in the upper dermis, VEGF may also 
contribute to keratinocyte proliferation and epidermal barrier homeostasis (Elias et al., 2008; 
Heidenreich et al., 2009). In psoriatic skin, the VEGF receptors VEGFR-1 and -2 are 
detectable and functional in keratinocytes (Man et al., 2006). As VEGF is secreted by 
keratinocytes and induces VEGFR expression in the same cells, VEGF may also contribute to 
keratinocyte hyperproliferation in psoriasis in an autocrine manner. This could be relevant 
when psoriasis is triggered by external injury (Koebner phenomenon) and interestingly 
disruption of the epidermal barrier homeostasis induces VEGF expression (Elias et al., 2008). 
Further evidence for a role of VEGF in keratinocyte proliferation comes from transgenic 
mice deficient in epidermal VEGF: these animals have delayed permeability barrier recovery 
after acute perturbation, decreased density of dermal blood vessels and lack epidermal 
hyperplasia as well as angiogenesis in response to sustained barrier disruption (Elias et al., 
2008). Thus, physiological production of VEGF contributes to normal proliferation, 
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differentiation and function of the epidermis (Heidenreich et al., 2009). Consequently, VEGF 
over-expression in psoriasis might contribute to the epidermal changes observed in this 
disease. Although immune cells are also able to secrete VEGF, the findings of VEGF over-
expression in psoriatic epidermis together with the data reported from the transgenic 
animals strongly suggest that VEGF derived from epidermal keratinocytes acts as a key 
cytokine driving angiogenesis in psoriasis and as a central paracrine growth factor 
contributing to the pathology seen in psoriasis. 
3.3.2 Keratinocytes and C1d 
The expression of CD1d by normal human skin and its pronounced over-expression in 
psoriatic skin lesions is well documented (Bonish et al., 2000) as well as the presence of 
NK-T cells in the epidermis of acute and chronic psoriatic plaques (Nickoloff & Wrone-
Smith, 1999; Nickoloff et al., 2000). A hallmark of NK-T cells is their expression of certain 
C-type lectin NK cell receptors (NKRs)4 such as CD94 and CD161. Classical NK-T cells 
may plan an immunoregulatory role for recognition of both self and foreign antigens and 
are implicated in the pathogenesis of autoimmune and inflammatory diseases like 
psoriasis. An important clue to the function of NK-T cells is provided by their interaction 
with professional antigen presenting cells (APCs) via CD1d (Huang et al., 1999). CD1d 
has some similarities in structure to the major histocompatibility complex class II (MHC 
II) molecules. While initially CD1d was believed to bind and present peptide antigens to T 
cells (Castano et al., 1995), more recent studies highlight its ability to present glycolipids 
and GPI-linked proteins (Huang et al., 1999). NK-T cells can become activated in a CD1d-
restricted fashion with subsequent proliferation and cytokine production, including IFN-Ǆ 
and IL-4. Keratinocytes in vitro and in vivo synthesize and express CD1d, which is 
capable of triggering CD161+ NK-T cells to produce high levels of IFN-Ǆ, but not IL-4. The 
stimulation by CD1d of T cells bearing NK receptors preferentially induces a cytokine 
switch to IFN-Ǆ (Arase et al., 1996, 1997). Moreover, the differential induction of IFN-Ǆ 
production, but not IL-4, after the NK-T cell clones recognized CD1d on keratinocytes has 
potentially important implications for psoriasis. Not only is there over-expression of 
CD1d by psoriatic epidermal keratinocytes and the presence of NK-T cells bearing CD94 
and CD161, but the cytokine IFN-Ǆ has been shown to trigger psoriatic lesions (Fierlbeck 
et al., 1990). Therefore a positive feedback loop could be established in skin due to the 
presence of NK-T cells being activated to produce IFN-Ǆ upon contact with CD1d-positive 
keratinocytes, leading to further CD1d expression and subsequent NK-T cell release of 
more IFN-Ǆ. The lack of a proliferative response by NK-T cells to CD1d keratinocytes is 
also consistent with the general number and distribution of CD94- and CD161-positive 
NK-T cells in psoriasis. Thus, the NK-T cells are never observed in tight clusters or in very 
large numbers as might be expected if they were undergoing a local proliferative 
response; rather, they are found as more evenly distributed single cells throughout a 
psoriatic plaque. In normal human skin CD1d is generally restricted to the outermost 
keratinocyte layers in the stratum granulosum just beneath the lipid-rich stratum 
corneum. In addition to epidermal keratinocytes, CD1d is detected on upper dermal 
dendritic cells, endothelium, eccrine ducts, acrosyringium, and the pilo-sebaceous unit, 
except for the dermal papillae and hair matrix cells. In psoriatic plaques CD1d expression 
was increased compared with that in normal and symptomless skin, beginning in the 
supra-basilar layer and extending to the outermost keratinocytes immediately beneath the 
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parakeratotic layer juxtaposed to the stratum corneum. CD161-positive T cells were 
frequently observed in direct contact with keratinocytes expressing CD1d in psoriatic 
plaques. Given this anatomical juxtaposition, it is possible for various types of glycolipids 
in the psoriatic scale to be directly exposed to the abundant keratinocyte cell surface 
CD1d. Moreover, given the large hydrophobic binding pockets in CD1d, the presence of 
CD1d on the outer layers of epidermis in psoriatic plaques opens up the possibility that 
various glycolipids present in the stratum corneum could play a role in triggering a 
response by NK-T cells or other T cell subsets capable of recognizing such glycolipids in 
the context of CD1d. During epidermal differentiation keratinocytes produce different 
amounts and types of various glycolipids, including glucosylceramides (Holleran et al., 
1993). Alterations in these glycolipids in the stratum corneum can have a significant 
impact on the barrier function of skin. However, it is also clear that barrier perturbation 
can initiate cytokine cascades and thus influence inflammatory and mononuclear cell 
activation (Nickoloff & Naidu, 1994). A cycle can be envisioned in which pathogenic NK-
T cells initiate barrier abnormality, which, in turn, would generate glycolipids that could 
be presented by keratinocyte CD1d and further activate CD161+ T cells in psoriasis 
(Kalish et al., 1994). Taken together, these findings support the idea that NK-T cells may 
play an important patho-physiological role in psoriasis. Besides the ability of 
keratinocytes to initiate (Barker et al., 1991), perpetuate (Nickoloff & Turka, 1994), and 
terminate (Guttierrez-Steil et al., 1998) immune reactions involving conventional T cell 
responses to nominal antigens and super-antigens, CD1d expression may also imbue the 
keratinocyte with the capacity to interact with NKR-bearing T cells. As a member of a 
non-classical, MHC independent, antigen-presenting system, CD1d expression as seen in 
psoriasis provides a novel opportunity for therapeutic targeting and for understanding 
the immunologic and genetic basis of psoriasis as well as the potential role for innate 
immunity in psoriasis (Nickoloff, 1999a, 1999b). 
4. Conclusion  
The pathogenesis of psoriasis is considered to be an immunologically mediated process that 
takes place upon a favourable genetic background. According to this view, the presence of a 
yet unknown (auto)-antigen causes the generation of effector T-cells that infiltrate the skin 
and initiate the inflammatory process. Over its course, cutaneous infiltration of various 
immune cell populations and, subsequently, an activation of numerous immune and tissue 
cells in the skin takes place. Two fundamentally different cell types interact in the formation 
of a psoriatic lesion: epidermal keratinocytes and mononuclear leukocytes. Whereas 
keratinocytes might be viewed only as bystander cells in terms of immune activation, it is 
more likely that they are active participants in the recruitment and activation of leukocytes 
in psoriatic lesions: the interplay between keratinocytes and immune cells can be considered 
the main feature of the psoriasis pathogenesis. In facts whatever the sequence of events that 
leads to the induction of the mentioned cytokines and mediators in epidermal keratinocytes, 
it is highly likely that they significantly contribute to the typical changes observed in 
psoriatic lesions; cytokine or growth factor secretion by epidermal keratinocytes can be 
sufficient to recruit immune cells into the skin and induce a hyperplastic epidermis with 
hyperkeratosis and reproduce features of psoriatic disease. Regulation of the inflammatory 
events initiated or perpetuated by keratinocytes could so represent an important strategy for 
the treatment of psoriasis and other chronic inflammatory skin diseases. 
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